Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2006
The prevalence of CDKN2A germ-line mutations and relative risk for cutaneous malignant melanoma: an international population-based study.
Сравнительное исследованиеСтатьяМногоцентровое исследованиеПоддержка NIH: внешняя программаПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Berwick Marianne, Orlow Irene, Hummer Amanda J, Armstrong Bruce K, Kricker Anne, Marrett Loraine D, Millikan Robert C, Gruber Stephen B, Anton-Culver Hoda, Zanetti Roberto, Gallagher Richard P, Dwyer Terence, Rebbeck Timothy R, Kanetsky Peter A, Busam Klaus, From Lynn, Mujumdar Urvi, Wilcox Homer, Begg Colin B, GEM Study Group
Аннотация
Germ-line mutations of CDKN2A have been identified as strong risk factors for melanoma in studies of multiple-case families. However, an assessment of their relative risk for melanoma in the general population has been difficult because they occur infrequently. We addressed this issue using a novel population-based case-control study design in which "cases" have incident second- or higher-order melanomas [multiple primary melanoma (MPM)] and "controls" have incident first primary melanoma [single primary melanoma (SPM)]. Participants were ascertained from nine geographic regions in Australia, Canada, Italy, and United States. In the 1,189 MPM cases and 2,424 SPM controls who were eligible and available for analysis, the relative risk of a subsequent melanoma among patients with functional mutations who have an existing diagnosis of melanoma, after adjustments for age, sex, center, and known phenotypic risk factors, is estimated to be 4.3 (95% confidence interval, 2.3-7.7). The odds ratio varied significantly depending on the type of mutation involved. The results suggest that the relative risk of mutation carriers in the population may be lower than currently believed and that different mutations on the CDKN2A gene may confer substantially different risks of melanoma.
Предметные рубрики MeSH
AgedAustraliaCanadaCase-Control StudiesChromatography, High Pressure LiquidCyclin-Dependent Kinase Inhibitor p16ExonsFemaleGerm-Line MutationHumansInternational AgenciesIntronsItalyMaleMelanomaMiddle AgedNeoplasms, Multiple PrimaryPolymerase Chain ReactionPolymorphism, GeneticSkin NeoplasmsUnited States